• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Øvrige samlinger
  • Publikasjoner fra CRIStin - NTNU
  • View Item
  •   Home
  • Øvrige samlinger
  • Publikasjoner fra CRIStin - NTNU
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Pneumonitis and fibrosis after breast cancer radiotherapy: occurrence and treatment-related predictors

Karlsen, Jarle; Tandstad, Torgrim; Sowa, Piotr; Salvesen, Øyvind; Stenehjem, Jo S.; Lundgren, Steinar; Reidunsdatter, Randi Johansen
Peer reviewed, Journal article
Accepted version
Thumbnail
View/Open
Karlsen (509.4Kb)
URI
https://hdl.handle.net/11250/2989310
Date
2021
Metadata
Show full item record
Collections
  • Institutt for klinisk og molekylær medisin [3285]
  • Institutt for samfunnsmedisin og sykepleie [3379]
  • Institutt for sirkulasjon og bildediagnostikk [1774]
  • Publikasjoner fra CRIStin - NTNU [34929]
  • Publikasjoner fra Cristin - St. Olavs hospital [1327]
  • St. Olavs hospital [2238]
Original version
Acta Oncologica. 2021, 60 (12)   10.1080/0284186X.2021.1976828
Abstract
Background Radiation pneumonitis (RP) and radiation fibrosis (RF) are common side effects after breast cancer (BC) radiotherapy (RT). However, there is a great variation in the frequency of RP and RF. This study presents the occurrence of- and the treatment-related predictors for RP and RF. Further, physician- and patient-reported pulmonary symptoms during the first year after postoperative RT for BC are demonstrated. Materials and methods From 2007 to 2008, 250 BC patients referred for postoperative RT were included in a prospective cohort study and followed during the first year after RT. High-resolution computed tomography of the lungs and symptom registration were performed before RT and 3, 6, and 12 months after RT. Patient-reported symptoms were registered by standard quality of life questionnaires. Logistic regression analyses were applied to estimate treatment-related predictors for radiological RP (rRP), clinical RP (cRP), radiological RF (rRF), and clinical RF (cRF). Results The occurrence of rRP and cRP at three months was 78% and 19%, while 12 months after RT rRF and cRF was 89% and 16%, respectively; all reported as grade 1. In multivariable analyses, mastectomy predicted cRP at three months (OR = 2.48, p = .03) and cRF at six months, ipsilateral lung volume receiving 20 Gray or more (V20), V30, and mean lung dose (MLD) predicted rRP at six months (OR = 1.06, p = .0003; OR = 1.10, p = .001; and OR = 1.03, p = .01, respectively). Endocrine treatment predicted cRF at 12 months (OR = 2.48, p = .02). Physicians reported significant more dyspnea at 3 months (p = .003) and patients reported ‘a little dyspnea’ more at 3 and 12 months compared to baseline (p = .007). Conclusion RP and RF are prevalent in the first year after BC radiation. Mastectomy predicted cRP at three months. V20, V30, D25, and MLD predicted rRP at 6 months, and endocrine treatment predicted cRF at 12 months. Patients and physicians reported dyspnea differently.
Publisher
Taylor & Francis
Journal
Acta Oncologica
Copyright
(C) Acta Oncologica

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit